| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition in which the half-life of a toxin peptide with a very short half-life in vivo (about 4 hours) is extended. <P>SOLUTION: An obtained composition and a multimer thereof include a half-life extending moiety, and linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide. The pharmaceutical composition comprises the obtained composition and a pharmaceutically acceptable carrier. A DNA encoding the composition, an expression vector comprising the DNA, and a host cell comprising the expression vector are also disclosed. Methods for treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, transplant rejection, graft-versus-host disease, and lupus, and for preventing or mitigating a relapse of symptoms of multiple sclerosis are also disclosed. The composition incorporating the toxin peptide has activity and/or ion channel target selectivity comparable to or even greater than an unconjugated peptide. <P>COPYRIGHT: (C)2012,JPO&INPIT |
